Canaccord Genuity Group Reiterates Buy Rating for Fractyl Health (NASDAQ:GUTS)

Fractyl Health (NASDAQ:GUTS)‘s stock had its “buy” rating reissued by Canaccord Genuity Group in a research report issued to clients and investors on Thursday,Benzinga reports. They currently have a $8.00 price objective on the stock.

A number of other brokerages have also recently commented on GUTS. Morgan Stanley cut shares of Fractyl Health from an “overweight” rating to an “equal weight” rating and reduced their target price for the company from $8.00 to $2.00 in a report on Thursday, January 29th. HC Wainwright reissued a “buy” rating and set a $8.00 price objective on shares of Fractyl Health in a research report on Tuesday, December 2nd. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Fractyl Health in a research note on Monday, December 29th. Three equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus price target of $5.40.

Fractyl Health Trading Down 5.2%

Fractyl Health stock opened at $0.45 on Thursday. Fractyl Health has a 52-week low of $0.38 and a 52-week high of $3.03. The company has a market cap of $71.17 million, a P/E ratio of -0.24 and a beta of 1.51. The company has a quick ratio of 4.27, a current ratio of 4.78 and a debt-to-equity ratio of 3.23. The business has a 50-day simple moving average of $0.71 and a two-hundred day simple moving average of $1.28.

Fractyl Health (NASDAQ:GUTS) last issued its quarterly earnings data on Tuesday, March 24th. The company reported $0.15 earnings per share for the quarter, topping the consensus estimate of ($0.19) by $0.34. Analysts predict that Fractyl Health will post -1.61 EPS for the current year.

Institutional Investors Weigh In On Fractyl Health

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Nantahala Capital Management LLC purchased a new position in Fractyl Health during the third quarter valued at approximately $19,298,000. 683 Capital Management LLC boosted its position in shares of Fractyl Health by 30.1% in the fourth quarter. 683 Capital Management LLC now owns 6,047,620 shares of the company’s stock worth $13,305,000 after purchasing an additional 1,397,620 shares during the period. Marshall Wace LLP increased its stake in shares of Fractyl Health by 234.9% in the fourth quarter. Marshall Wace LLP now owns 5,926,745 shares of the company’s stock worth $13,039,000 after purchasing an additional 4,156,969 shares in the last quarter. Alyeska Investment Group L.P. purchased a new stake in shares of Fractyl Health in the third quarter worth $8,981,000. Finally, Woodline Partners LP raised its position in shares of Fractyl Health by 821.1% during the 3rd quarter. Woodline Partners LP now owns 5,506,534 shares of the company’s stock valued at $8,755,000 after purchasing an additional 4,908,693 shares during the period.

Key Fractyl Health News

Here are the key news stories impacting Fractyl Health this week:

• Positive Sentiment: HC Wainwright raised multi‑year EPS forecasts (notably FY2026–FY2030) and trimmed near‑term loss estimates while keeping a “Buy” rating and an $8.00 price target — this signals the analyst expects meaningful recovery and eventual profitability, supporting upside versus the current sub‑$1 trade. HC Wainwright analyst note (MarketBeat)
• Positive Sentiment: Canaccord Genuity reaffirmed a “Buy” rating and an $8.00 price target, echoing the bullish analyst narrative and providing additional third‑party validation of the longer‑term thesis. Canaccord reaffirmation (Benzinga)
• Neutral Sentiment: Q4 2025 earnings call transcript is available — the company recently reported an EPS beat for Q4 (reported EPS vs. consensus), which is supportive but investors will focus on follow‑up cadence, cash runway, and clinical/regulatory catalysts. Q4 2025 earnings call transcript (MSN)
• Negative Sentiment: TipRanks flagged “significant compliance risks” under global anti‑corruption and sanctions laws after a new risk disclosure — legal/compliance issues can slow partnerships, delay commercial progress, or increase remediation costs, creating downside risk and adding near‑term uncertainty. Compliance risk disclosure (TipRanks)

Fractyl Health Company Profile

Fractyl Health, Inc is a clinical-stage medical technology company focused on the development and commercialization of minimally invasive, endoscopic therapies for metabolic diseases. Headquartered in Lexington, Massachusetts, Fractyl is advancing treatments that target the underlying physiology of conditions such as type 2 diabetes, obesity and nonalcoholic fatty liver disease (NAFLD) by modifying the duodenal mucosa to improve metabolic control.

The company’s lead product, Revita® Duodenal Mucosal Resurfacing (Revita DMR), employs a catheter-based hydrothermal ablation technique to remodel the lining of the upper small intestine.